Associate Director, Global Pricing Strategy & Analytics

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$177K-$221K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$111,944 U.S. median for this role

Projected growth (BLS Employment Projections)

+13.7% - Much faster than average

78% above the BLS role benchmark for data and ml aggregate.

Matched to SOC 15-1252 - Data and ML aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Data From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Work mode

Remote From the posting source checked Jun 20, 2026

In-office days

0 days From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Growth-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Associate Director, Global Pricing Strategy & Analytics Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: The Associate Director, Global Pricing Strategy & Analytics will play a critical role in shaping and executing global pricing strategies across the portfolio. This individual will lead the development of pricing frameworks, provide advanced analytics, and generate insights to support value optimization and market access decisions. The role requires strong cross-functional collaboration with Market Access, Commercial, Finance, HEOR, and Regional teams to ensure pricing strategies are aligned with business objectives and external market dynamics. Key Responsibilities: Global Pricing Strategy - Support the development and execution of global pricing strategies for pipeline products across key markets. - Establish pricing guidance, guardrails, and launch sequencing strategies to optimize global value. - Evaluate pricing scenarios considering payer dynamics, competitive landscape, and regulatory constraints. - Support early asset strategy by integrating pricing considerations into clinical and commercial planning. Analytics & Insights - Design and deliver advanced

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.